Artelo Biosciences (ARTL) Enterprise Value (2014 - 2025)
Artelo Biosciences (ARTL) posted quarterly Enterprise Value of -$600000.0 for Q4 2025, up 74.34% year-over-year from -$344160.9 in Q4 2024, and up 65.12% quarter-over-quarter from -$1.7 million in Q3 2025.
Artelo Biosciences (ARTL) Enterprise Value (2014 - 2025) Analysis & Trends
Artelo Biosciences (ARTL) has reported Enterprise Value for 12 consecutive years, with -$600000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Enterprise Value rose 74.34% year-over-year to -$600000.0; the TTM figure through Dec 2025 stood at -$600000.0 (up 74.34% YoY), while the FY2025 annual figure was -$600000.0, up 74.34% from the prior year.
- Enterprise Value climbed to -$600000.0 in Q4 2025 per ARTL's latest filing, from -$1.7 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$600000.0 in Q4 2025 and bottomed at -$26.4 million in Q4 2021.
- Historically, Enterprise Value has averaged -$7.3 million across 5 years, with a median of -$6.8 million in 2021.
- Annual changes were most pronounced in 2021 — Enterprise Value slumped 685.79% — and 2025, when it surged 90.2%.
- Artelo Biosciences' Enterprise Value stood at -$26.4 million in 2021, then jumped by 68.2% to -$8.4 million in 2022, then decreased by 24.37% to -$10.4 million in 2023, then surged by 77.58% to -$2.3 million in 2024, then jumped by 74.34% to -$600000.0 in 2025.
- Business Quant data shows ARTL's Enterprise Value at -$600000.0 in Q4 2025, -$1.7 million in Q3 2025, and -$2.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | 2.12 Bn |
| 10 | Artelo Biosciences | 113,239.32 | -486,760.68 | - | -600,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -600,000.00 |
| Sep 30, 2025 | -1.72 Mn |
| Jun 30, 2025 | -2.07 Mn |
| Mar 31, 2025 | -746,000.00 |
| Dec 31, 2024 | -2.34 Mn |
| Sep 30, 2024 | -4.86 Mn |
| Jun 30, 2024 | -5.60 Mn |
| Mar 31, 2024 | -7.61 Mn |
| Dec 31, 2023 | -10.43 Mn |
| Sep 30, 2023 | -2.64 Mn |
| Jun 30, 2023 | -5.72 Mn |
| Mar 31, 2023 | -6.92 Mn |
| Dec 31, 2022 | -8.38 Mn |
| Sep 30, 2022 | -8.62 Mn |
| Jun 30, 2022 | -12.12 Mn |
| Mar 31, 2022 | -12.35 Mn |
| Nov 30, 2021 | -26.37 Mn |
| Aug 31, 2021 | -6.63 Mn |
| May 31, 2021 | -10.05 Mn |
| Feb 28, 2021 | -11.22 Mn |